A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

British Journal of Cancer

Volumn 102, Issue 9, 2010, Pages 1355-1360

  Rustin, G J ^a   Shreeves, G ^a   Nathan, P D ^a   Gaya, A ^a   Ganesan, T S ^b   Wang, D ^c   Boxall, J ^a   Poupard, L ^a   Chaplin, D J ^d   Stratford, M R L ^e   Balkissoon, J ^d   Zweifel, M ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d OXiGENE Inc   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CA4P; Carboplatin; Combretastatin A4 phosphate; Paclitaxel; Phase I trial; Vascular disrupting agent

Indexed keywords

CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; DEXAMETHASONE; HEMOGLOBIN; METOCLOPRAMIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AGITATION; ALLERGIC REACTION; ALOPECIA; ANAPHYLACTIC SHOCK; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BLOOD PRESSURE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHASIA; EDEMA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; INCONTINENCE; INFECTION; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVARY CANCER; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RASH; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SMALL CELL CARCINOMA; STATISTICAL ANALYSIS; STOMATITIS; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATAXIA; CARBOPLATIN; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIFE EXPECTANCY; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT SELECTION; STILBENES;

EID: 77951667223     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605650     Document Type: Article

References (24)

1. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21(15): 2823-2830
2. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ (2005) Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 11(4): 1527-1533
3. Cooney MM, Savvides P, Agarwala S, Wang D, Flick S, Bergant S, Bhakta S, Lavertu P, Ortiz J, Remick S (2006) Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I, (18S): 5580
4. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62(June 15): 3408-3416
5. El Zayat AA, Degen D, Drabek S, Clark GM, Pettit GR, Von Hoff DD (1993) In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 4(1): 19-25
6. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21(15): 2831-2842
7. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC (2000) Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anti-cancer Res 20(1A): 229-233
8. Ke Q, Bodyak N, Rigor DL, Hurst NW, Chaplin DJ, Kang PM (2009) Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats. Vascul Pharmacol 51(5-6): 337-343
9. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, Stockx L, Wynendaele W, Fowler JF, Maleux G, Van den Bogaert W, Anne J, van Oosterom A, Lambin P (2000) Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 36(14): 1833-1843
10. Murata R, Siemann DW, Overgaard J, Horsman MR (2001) Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60(2): 155-161
11. Patterson DM, Rustin GJ (2007) Vascular damaging agents. Clin Oncol (R Coll Radiol) 19(6): 443-456
12. Rustin GJ (2003) Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials. J Clin Oncol 21(10 Suppl): 187-193
13. Rustin G, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G (2003b) Dimethyl-xanthenone-4- acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. BJC 88: 1160-1167
14. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM (2003a) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21(15): 2815-2822 (Pubitemid 46621828)
15. Salmon BA, Siemann DW (2007) Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys 68(1): 211-217
16. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313(5794): 1785-1787
17. Siemann DW, Mercer E, Lepler S, Rojiani AM (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99(1): 1-6
18. Staflin K, Jarnum S, Hua J, Honeth G, Kannisto P, Lindvall M (2006) Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma. Int J Gynecol Cancer 16(4): 1557-1564
19. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21(23): 4428-4438
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216
21. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59(7): 1626-1634
22. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials G (2004) Phase III randomized trial of docetaxel-carboplatin vs paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22): 1682-1691
23. Wildiers H, Ahmed B, Guetens G, De Boeck G, de Bruijn EA, Landuyt W, van Oosterom AT (2004) Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer 40(2): 284-290
24. Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D (2007) Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 92(8): 2902-2909